JPWO2022235558A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022235558A5
JPWO2022235558A5 JP2023567930A JP2023567930A JPWO2022235558A5 JP WO2022235558 A5 JPWO2022235558 A5 JP WO2022235558A5 JP 2023567930 A JP2023567930 A JP 2023567930A JP 2023567930 A JP2023567930 A JP 2023567930A JP WO2022235558 A5 JPWO2022235558 A5 JP WO2022235558A5
Authority
JP
Japan
Prior art keywords
methyl
carboxamide
oxopiperazine
chloro
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023567930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519487A (ja
JP2024519487A5 (https=
JP7846132B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027262 external-priority patent/WO2022235558A1/en
Publication of JP2024519487A publication Critical patent/JP2024519487A/ja
Publication of JP2024519487A5 publication Critical patent/JP2024519487A5/ja
Publication of JPWO2022235558A5 publication Critical patent/JPWO2022235558A5/ja
Application granted granted Critical
Publication of JP7846132B2 publication Critical patent/JP7846132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023567930A 2021-05-07 2022-05-02 Nav1.8阻害薬としてのアリール 3-オキソピペラジンカルボキサミド類及びヘテロアリール 3-オキソピペラジンカルボキサミド類 Active JP7846132B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185608P 2021-05-07 2021-05-07
US63/185,608 2021-05-07
PCT/US2022/027262 WO2022235558A1 (en) 2021-05-07 2022-05-02 Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors

Publications (4)

Publication Number Publication Date
JP2024519487A JP2024519487A (ja) 2024-05-14
JP2024519487A5 JP2024519487A5 (https=) 2024-06-05
JPWO2022235558A5 true JPWO2022235558A5 (https=) 2024-06-05
JP7846132B2 JP7846132B2 (ja) 2026-04-14

Family

ID=83932809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567930A Active JP7846132B2 (ja) 2021-05-07 2022-05-02 Nav1.8阻害薬としてのアリール 3-オキソピペラジンカルボキサミド類及びヘテロアリール 3-オキソピペラジンカルボキサミド類

Country Status (10)

Country Link
US (1) US20240246932A1 (https=)
EP (1) EP4334306A4 (https=)
JP (1) JP7846132B2 (https=)
KR (1) KR20240006606A (https=)
CN (1) CN117597339A (https=)
AU (1) AU2022270061B2 (https=)
BR (1) BR112023023186A2 (https=)
CA (1) CA3217605A1 (https=)
MX (1) MX2023013147A (https=)
WO (1) WO2022235558A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025513452A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor
GEAP202516634A (en) 2022-04-22 2025-02-25 Vertex Pharma Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023391870A1 (en) 2022-12-06 2025-06-05 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025122953A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002410A (es) * 2004-08-30 2007-05-07 Neuromed Pharmaceuticals Ltd Derivados de urea como bloqueadores de canal de calcio.
US7767680B2 (en) * 2004-11-03 2010-08-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
JP5361857B2 (ja) * 2007-03-23 2013-12-04 ファイザー・リミテッド イオンチャネルの阻害剤
WO2011026240A1 (en) * 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
EP3873893A1 (en) * 2018-11-02 2021-09-08 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
GEP20257750B (en) * 2020-06-17 2025-03-25 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
JP2023530319A (ja) * 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害剤としての2-オキソ-オキサゾリジン-5-カルボキサミド
BR112022024476A2 (pt) * 2020-06-17 2022-12-27 Merck Sharp & Dohme Llc 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8
EP4334293A1 (en) * 2021-05-07 2024-03-13 Merck Sharp & Dohme LLC Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors

Similar Documents

Publication Publication Date Title
IL299180A (en) 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS
JPWO2022235558A5 (https=)
JP2024038267A5 (https=)
JPWO2021257418A5 (https=)
JPWO2021257420A5 (https=)
JP2017505790A5 (https=)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2004506718A5 (https=)
JP2001526223A5 (https=)
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
JP2018515555A5 (https=)
JP2019533694A5 (https=)
JP2016514711A5 (https=)
JP2018519323A5 (https=)
JP2016523976A5 (https=)
JP2017525757A5 (https=)
JP2013501749A5 (https=)
JP2009536196A5 (https=)
JP2004504301A5 (https=)
RU2015100942A (ru) Производное пиперидинилпиразолпиридина
JPWO2023064857A5 (https=)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2013531070A5 (https=)
RU2017145929A (ru) МОДУЛЯТОРЫ ROR ГАММА(RORγ)
RU2019136279A (ru) C5 -Анилинохиназолиновые соединения и их использование в лечении рака